To send content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about sending content to .
To send content items to your Kindle, first ensure firstname.lastname@example.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about sending to your Kindle.
Note you can select to send to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Anthony B. Ward, Consultant in Rehabilitation Medicine North Staffordshire Rehabilitation Centre, University Hospital of North Staffordshire, Stoke-on-Trent, UK,
Sajida Javaid, Specialist Registrar in Rehabilitation Medicine North Staffordshire Rehabilitation Centre, University Hospital of North Staffordshire, Stoke-on-Trent, UK
The management of spasticity requires a multi-professional approach based on addressing the troublesome effects of the increased tone. This chapter discusses the oral agents and their place in overall management strategies. Oral antispastic agents are usually indicated in patients with diffuse or regional muscle spasticity rather than localized muscle spasticity. Despite the large number of drugs that have been reported to influence muscle tone, very few have been found useful in clinical practice. The commonly used antispastic drugs are baclofen, benzodiazepine, dantrolene sodium and tizanidine. The drugs can be used alone as monotherapy or in combination to reduce the spasticity effectively. Cannabis has been widely discussed, but there is no evidence that it has a sustained effect as an antispastic drug (CAMS Study), where as baclofen is a structural analogue of gamma amino butyric acid (GABA), which is one of the main inhibitory neurotransmitters in the central nervous system.
Michael P. Barnes, Walkergate Park, International Centre for Neurorehabilitation and Neuropsychiatry, Newcastle upon Tyne, UK,
Anthony B. Ward, North Staffordshire Rehabilitation Centre, Stoke-on-Trent, UK
This book has been written to highlight the remarkable progress in the application of botulinum toxin in medical practice. It is used across many specialties and has an increasing indication across a whole spectrum of diseases. As a result, its commercial sales have grown exponentially and its use in cosmesis has made ‘BOTOX®’ a household name. This is extraordinary after such a short time in this field and some other products have even gone so far as to add an ‘-ox’ on the end of their brand name to attempt to capture some of the kudos (and market) of botulinum toxin. This is of course very different from when the drug was first marketed and when it was regarded as a highly dangerous product. The indications for botulinum toxin treatment are listed in Chapter 5. In many, there is still little or no evidence that it works, but in others, there is good evidence of its therapeutic benefit.
History of BoNT
Botulinum toxin was first identified as a poison in the nineteenth century. The toxin is a protein, which is produced by the Gram negative Clostridium botulinum bacterium. It is found in a variety of foods, but is most common in meat products. The name botulus means sausage and hence its terminology from its appearance in meat products. The features of botulism have been known since around the time of Christ and it was certainly described in the Middle Ages.
Botulinum toxins now play a very significant role in the management of a wide variety of medical conditions; from headaches to hypersalivation, and from spasticity to sweating. In this book, a strong, international team of experts outline the basic neurochemistry of botulinum toxins and chart the progress of the drug from laboratory to clinic. Then individual chapters summarize their use for the main clinical indications in the context of other available treatments. This book will be of interest to neuroscientists and practising clinicians working in a wide range of specialities, from neurology and dermatology to pediatrics, plastic surgery and rehabilitation medicine.
Spasticity is a physiological consequence of an insult to the brain or spinal cord, which can lead to life-threatening, disabling and costly consequences. This typically occurs in the following patients following stroke, brain injury (trauma and other causes, e.g. anoxia, post-neurosurgery), spinal cord injury, multiple sclerosis and other disabling neurological diseases, and cerebral palsy. Its current management has been advanced considerably over the last ten years by new thinking and by new drugs and technology. Lance's definition of 1980 is still relevant and the impairment is classified as one of the movement disorders. It is important therefore to stress when teaching on this topic, in order to highlight the need for patients' spasticity to be assessed while they are functioning. The fact that many attempts have been made to define it shows the degree of its complexity, but Young described spasticity as part of the upper motor neuron syndrome and gave a definition as a velocity-dependent increase in muscle tone with exaggerated tendon jerks resulting in hyper-excitability of the stretch reflex in association with other features of the upper motor neuron syndrome.
He also described spastic dystonia and spastic paresis, which are somewhat contentious terms, but do highlight the positive and negative features of the upper motor neuron syndrome and these are set out in Table 8.1. Essentially, if left untreated following damage to the brain or spinal cord, it is characterized by muscle overactivity and high-tone spasms and will lead to muscle and soft tissue contracture.
Email your librarian or administrator to recommend adding this to your organisation's collection.